Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
6/2/26 Bristol Myers Squibb (BMY) Iza-bren for Triple-Negative Breast Cancer (TNBC) Subscribers Only Subscribers Only Subscribers Only
6/2/26 AstraZeneca (AZN) camizestrant for Breast Cancer Subscribers Only Subscribers Only Subscribers Only
6/2/26 AstraZeneca (AZN) camizestrant for HR+/HER2- Breast Cancer Subscribers Only Subscribers Only Subscribers Only
6/1/26 AstraZeneca (AZN) Imfinzi for Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) Subscribers Only Subscribers Only Subscribers Only
6/1/26 AstraZeneca (AZN) Imjudo for Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/26/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/08/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/17/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update